BioSpace News Archive

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2022 after the market closes on Thursday, November 3, 2022.

Travere Therapeutics, Inc. announced that the Company and its collaborators will present data from its sparsentan programs, including long-term clinical data from the ongoing Phase 2 DUET Study in focal segmental glomerulosclerosis, as well as non-clinical data exploring the potential for sparsentan to protect kidney function at the American Society of Nephrology Kidney Week 2022.

The Board of Directors of Cigna Corporation declared a cash dividend of $1.12 per share of Cigna common stock, payable on December 21, 2022 to shareholders of record as of the close of business on December 6, 2022.

Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”) today announced that it will release financial results for the third quarter of 2022 after the close of trading on Wednesday, November 2, 2022.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for ALPN-303’s phase 1 study (RUBY-1) at upcoming scientific conferences.

Complete Genomics, part of MGI, celebrates the US commercial launch of their DNBSEQTM sequencing product line at the American Society of Human Genetics Annual Meeting, from October 25-29, in Los Angeles.

RELIEF THERAPEUTICS Holding SA today announced that they and NRx Pharmaceuticals, Inc. have agreed to extend the stay of their pending litigation until November 7, 2022 to allow time for the parties to finalize their tentative litigation settlement.

Vaxcyte, Inc., a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

Dassault Systèmes and Sanofi announced their partnership to optimize “EVolutive Facility” production at Sanofi’s future state-of-the-art modular manufacturing facilities in France and Singapore.

Verona Pharma plc announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.